The factor XIIa blocking antibody 3F7: A safe anticoagulant with anti-inflammatory activities

Annals of Translational Medicine

Volumn 3, Issue 17, 2015, Pages

  Worm, Marie ^a   Köhler, Elodie C ^a   Panda, Rachita ^a   Long, Andy ^a   Butler, Lynn M ^a,b   Stavrou, Evi X ^c,d   Nickel, Katrin F ^a,b   Fuchs, Tobias A ^a,b   Renné, Thomas ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angioedema; Anticoagulation; Cardiovascular; Coagulation; Factor XII (FXII); Hereditary angioedema (HAE) type III; Thrombosis

Indexed keywords

EID: 85015472126     PISSN: 23055839     EISSN: 23055847     Source Type: Journal    
DOI: 10.3978/j.issn.2305-5839.2015.09.07     Document Type: Review

References (45)

1. Renné T. The procoagulant and proinflammatory plasma contact system. Semin Immunopathol 2012;34:31-41.
2. Renné T, Schmaier AH, Nickel KF, et al. In vivo roles of factor XII. Blood 2012;120:4296-303.
3. Stavrou E, Schmaier AH. Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. Thromb Res 2010;125:210-5.
4. Maas C, Renné T. Regulatory mechanisms of the plasma contact system. Thromb Res 2012;129 Suppl 2:S73-6.
5. Kenne E, Renné T. Factor XII: a drug target for safe interference with thrombosis and inflammation. Drug Discov Today 2014;19:1459-64.
6. Renné T, Gailani D, Meijers JC, et al. Characterization of the H-kininogen-binding site on factor XI: a comparison of factor XI and plasma prekallikrein. J Biol Chem 2002;277:4892-9.
7. Renné T, Dedio J, Meijers JC, et al. Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2. J Biol Chem 1999;274:25777-84.
8. Björkqvist J, Sala-Cunill A, Renné T. Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost 2013;109:368-74.
9. Mackman N. Tissue-specific hemostasis: role of tissue factor. J Thromb Haemost 2008;6:303-5.
10. Renné T, Oschatz C, Seifert S, et al. Factor XI deficiency in animal models. J Thromb Haemost 2009;7 Suppl 1:79-83.
11. Lämmle B, Wuillemin WA, Huber I, et al. Thromboembolism and bleeding tendency in congenital factor XII deficiency-a study on 74 subjects from 14 Swiss families. Thromb Haemost 1991;65:117-21.
12. Müller F, Gailani D, Renné T. Factor XI and XII as antithrombotic targets. Curr Opin Hematol 2011;18:349-55.
13. Renné T, Pozgajová M, Grüner S, et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005;202:271-81.
14. Stavrou EX, Fang C, Merkulova A, et al. Reduced thrombosis in Klkb1-/-mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood 2015;125:710-9.
15. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006;203:513-8.
16. Pauer HU, Renné T, Hemmerlein B, et al. Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thromb Haemost 2004;92:503-8.
17. Konings J, Govers-Riemslag JW, Philippou H, et al. Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood 2011;118:3942-51.
18. Tse K, Zuraw BL. Recognizing and managing hereditary angioedema. Cleve Clin J Med 2013;80:297-308.
19. Bork K, Barnstedt SE, Koch P, et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000;356:213-7.
20. Cichon S, Martin L, Hennies HC, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006;79:1098-104.
21. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006;343:1286-9.
22. Björkqvist J, de Maat S, Lewandrowski U, et al. Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J Clin Invest 2015;125:3132-46.
23. Mutch NJ, Waters EK, Morrissey JH. Immobilized transition metal ions stimulate contact activation and drive factor XII-mediated coagulation. J Thromb Haemost 2012;10:2108-15.
24. Svensson M, Friberger P, Lundström O, et al. Activation of FXII during haemodialysis. Scand J Clin Lab Invest 1996;56:649-52.
25. Oschatz C, Maas C, Lecher B, et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011;34:258-68.
26. Sala-Cunill A, Björkqvist J, Senter R, et al. Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. J Allergy Clin Immunol 2015;135:1031-43.e6.
27. Maas C, Govers-Riemslag JW, Bouma B, et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008;118:3208-18.
28. Zamolodchikov D, Chen ZL, Conti BA, et al. Activation of the factor XII-driven contact system in Alzheimer's disease patient and mouse model plasma. Proc Natl Acad Sci U S A 2015;112:4068-73.
29. Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 2007;104:6388-93.
30. Fuchs TA, Abed U, Goosmann C, et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007;176:231-41.
31. Oehmcke S, Mörgelin M, Herwald H. Activation of the human contact system on neutrophil extracellular traps. J Innate Immun 2009;1:225-30.
32. Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010;107:15880-5.
33. Jiménez-Alcázar M, Napirei M, Panda R, et al. Impaired DNase1-mediated degradation of neutrophil extracellular traps is associated with acute thrombotic microangiopathies. J Thromb Haemost 2015;13:732-42.
34. Ruiz FA, Lea CR, Oldfield E, et al. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem 2004;279:44250-7.
35. Smith SA, Mutch NJ, Baskar D, et al. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A 2006;103:903-8.
36. Müller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009;139:1143-56.
37. Müller F, Renné T. Platelet polyphosphates: the nexus of primary and secondary hemostasis. Scand J Clin Lab Invest 2011;71:82-6.
38. Ghosh S, Shukla D, Suman K, et al. Inositol hexakisphosphate kinase 1 maintains hemostasis in mice by regulating platelet polyphosphate levels. Blood 2013;122:1478-86.
39. Nickel KF, Spronk HM, Mutch NJ, et al. Time-dependent degradation and tissue factor addition mask the ability of platelet polyphosphates in activating factor XII-mediated coagulation. Blood 2013;122:3847-9.
40. Nickel KF, Ronquist G, Langer F, et al. The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood 2015;126:1379-89.
41. Kilinç E, Van Oerle R, Borissoff JI, et al. Factor XII activation is essential to sustain the procoagulant effects of particulate matter. J Thromb Haemost 2011;9:1359-67.
42. Larsson M, Rayzman V, Nolte MW, et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med. 2014;6:222ra17.
43. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363:513-22.
44. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010;363:523-31.
45. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010;363:532-41.